MyFinsight
Home
Blog
About
Cash and cash
equivalents
$9,900K
(1979.83%↑ Y/Y)
Prepaid expenses and
other current assets
$468K
(146.32%↑ Y/Y)
Marketable investments
$64K
(-82.17%↓ Y/Y)
Total current assets
$10,432K
(917.76%↑ Y/Y)
Patent and trademark
rights, net
$1,714K
(-20.94%↓ Y/Y)
Other assets
$271K
(-22.79%↓ Y/Y)
Right of use asset, net
$260K
(-47.58%↓ Y/Y)
Property and equipment,
net
$54K
(-39.33%↓ Y/Y)
Total assets
$12,731K
(208.33%↑ Y/Y)
Total liabilities and
stockholders equity
$12,731K
(208.33%↑ Y/Y)
Total stockholders
equity (deficit)
$7,744K
(218.30%↑ Y/Y)
Total liabilities
$4,987K
(-53.28%↓ Y/Y)
Accumulated deficit
-$447,597K
(-3.29%↓ Y/Y)
Additional paid-in capital
$455,312K
(6.69%↑ Y/Y)
Total current
liabilities
$4,946K
(-52.41%↓ Y/Y)
Operating lease liability
$41K
(-85.46%↓ Y/Y)
Common stock, 0.001 par
value, authorized...
$29K
(2800.00%↑ Y/Y)
Current portion of note
payable, net
$3,621K
(58.12%↑ Y/Y)
Accrued expenses
$586K
(2.27%↑ Y/Y)
Accounts payable
$480K
(-93.42%↓ Y/Y)
Current portion of
operating lease liability
$259K
(11.16%↑ Y/Y)
Back
Back
Balance Sheet
AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Inc. (AIM)
source: myfinsight.com